A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study

A. K. L. Reyners*, L. de Munck, F. L. G. Erdkamp, W. M. Smit, K. Hoekman, R. I. Lalisang, H. de Graaf, A. N. M. Wymenga, M. Polee, H. Hollema, M. A. T. M. van Vugt, M. Schaapveld, P. H. B. Willemse

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)2896-2902
JournalAnnals of Oncology
Volume23
Issue number11
DOIs
Publication statusPublished - Nov 2012

Keywords

  • carboplatin
  • celecoxib
  • docetaxel
  • epithelial ovarian cancer
  • first-line chemotherapy
  • randomized phase II study

Cite this